文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV-1整合酶N155H突变通路导致多替拉韦耐药

Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

报道一例接受多替拉韦单药治疗失败的患者,整合酶基因出现N155H-K211R-E212T突变,基线存在多态性K156N。无细胞和培养实验及分子建模显示,N155H联合K156N足以导致对多替拉韦的显著耐药,且需延长观察时间才能揭示耐药。

要点

  • 多替拉韦单药治疗失败可伴随整合酶N155H-K211R-E212T突变出现。
  • 基线多态性K156N作为次要突变增强N155H介导的多替拉韦耐药。
  • 评估多替拉韦耐药需考虑整合酶/DNA复合物稳定性并延长检测时间。

核心结论

  • 整合酶链转移抑制剂(STI)整合酶/DNA复合物的稳定性是评估多替拉韦耐药的重要参数。
  • 包含N155H的通路可在多替拉韦治疗患者中被选择,基线多态性K156N作为次要突变增强耐药。

研究设计与样本

  • 病例报告:一例接受多替拉韦单药治疗的患者,基线存在多态性K156N,治疗失败时出现整合酶N155H-K211R-E212T突变。
  • 采用无细胞实验、培养实验和分子建模研究N155H-K156N-K211R-E212T突变的影响。

主要发现

  • 无细胞和培养实验证实,在基线多态性K156N背景下,患者选择的突变导致对多替拉韦的高水平耐药,需在长于常规的时间点分析才能恰当揭示结果。
  • 仅N155H与K156N联合即足以导致对多替拉韦的显著耐药。
  • 建模研究显示,与野生型序列相比,多替拉韦在含突变整合酶/DNA复合物中稳定性更低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dolutegravir, an integrase strand-transfer inhibitor (STI), shows a high genetic barrier to resistance. Dolutegravir is reported to be effective against viruses resistant to raltegravir and elvitegravir. In this study, we report the case of a patient treated with dolutegravir monotherapy. Failure of dolutegravir treatment was observed concomitant with the appearance of N155H-K211R-E212T mutations in the integrase (IN) gene in addition to the polymorphic K156N mutation that was present at baseline in this patient. METHODS: The impact of N155H-K156N-K211R-E212T mutations was studied in cell-free, culture-based assays and by molecular modelling. RESULTS: Cell-free and culture-based assays confirm that selected mutations in the patient, in the context of the polymorphic mutation K156N present at the baseline, lead to high resistance to dolutegravir requiring that the analysis be done at timepoints longer than usual to properly reveal the results. Interestingly, the association of only N155H and K156N is sufficient for significant resistance to dolutegravir. Modelling studies showed that dolutegravir is less stable in IN/DNA complexes with respect to the WT sequence. CONCLUSIONS: Our results indicate that the stability of STI IN/DNA complexes is an important parameter that must be taken into account when evaluating dolutegravir resistance. This study confirms that a pathway including N155H can be selected in patients treated with dolutegravir with the help of the polymorphic K156N that acts as a secondary mutation that enhances the resistance to dolutegravir.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Malet I, Ambrosio FA, Subra F, et al. Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance. J Antimicrob Chemother. 2018. PMID: 29373677. doi:10.1093/jac/dkx529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。